TearScience Secures $70 Million For One-Of-A-Kind Eye Device
This article was originally published in Start Up
Executive Summary
TearScience Inc. is ready to go into full-scale commercialization for a new device treatment for the most prevalent form of dry eye. In late February, the young company secured up to $70 million from HealthCare Royalty Partners to help make that happen.
You may also be interested in...
OrbiMed Launches $600M Royalty Fund
The diversified investment firm will aim for low-risk investments that bring faster returns to inventors, research institutions and smaller drug developers.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.